JERSEY CITY, N.J.--(BUSINESS WIRE)--Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that the company’s two lead product candidates, LX211 for the treatment of uveitis and LX201 for the prevention of corneal transplant rejection, will be highlighted in multiple presentations at the 2008 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The international meeting is being held from April 27 – May 1 in Fort Lauderdale, Florida.
